基于4-1BB的采用性T细胞治疗的第一阶段试验,针对人类端粒酶逆转录酶,在患有晚期耐火实体瘤的患者中进行
Wonyoung Choi1, Youngjoo Lee2, Beom K Choi3
1Center for Clinical Trials, National Cancer Center, Goyang, Republic of Korea; Center for Rare Cancers, National Cancer Center, Goyang, Republic of Korea.
Cytotherapy
|August 26, 2023
概括
产生人类端粒酶逆转录酶特异性CD8+T细胞 (TERTiNTs) 对癌症患者来说是可行的和安全的. 这种方法在重度预先治疗的个体中显示出疾病稳定,表明抗癌治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
背景情况:
- 人类端粒酶逆转录酶 (hTERT) 是抗癌疗法的验证标.
- 开发特定于hTERT的CD8+T细胞 (TERTiNTs) 提供了一种新的治疗策略.
- 来自癌症患者的外周血液单核细胞 (PBMC) 是产生TERTiNTs的来源.
研究的目的:
- 评估生成和管理hTERT诱导的自然T细胞 (TERTiNTs) 的可行性和安全性.
- 评估TERTiNTs在对标准治疗耐药的固体癌症患者的治疗潜力.
主要方法:
- 一个单中心,第一阶段的剂量升级试验进行.
- 自主 CD8+ T 细胞是从患者的 PBMC 中使用 hTERT 生成的.
- 患者在淋巴损伤性化疗后接受了静脉注射TERTiNT输液.
主要成果:
- 招募了24名重度预治疗的患者.
- TERTiNT输液耐受性良好,没有观察到剂量限制性毒性.
- 七名患者 (30.4%) 的病情稳定,其中五分之四的最高剂量显示稳定.
结论:
- 第三代是可行的和安全的.
- 这种细胞疗法在晚期癌症患者中表现出显著的疾病控制率.
- TERTiNTs代表了一种有前途的方法来管理固体瘤.
更多相关视频
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
21.4K
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.0K
相关概念视频
Tumor Immunotherapy
555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
